Top

Hernia

Published in:

01-02-2011 | Original Article

Parecoxib sodium in the treatment of postoperative pain after Lichtenstein tension-free mesh inguinal hernia repair

Authors: A. V. Kyriakidis, I. Perysinakis, I. Alexandris, K. Athanasiou, Ch. Papadopoulos, I. Mpesikos

Published in: Hernia | Issue 1/2011

Abstract

Purpose

This prospective, randomized, double-blind study compared the analgesic efficacy and safety of parecoxib sodium versus lornoxicam and diclofenac, after Lichtenstein tension-free mesh inguinal hernia repair.

Methods

Patients were randomly assigned to receive parecoxib 80 mg daily i.v. (Group A), lornoxicam 16 mg daily i.v. (Group B) or diclofenac 150 mg daily i.m. (Group C). Rescue analgesia in all groups consisted of pethidine 25 mg i.m. Pain was measured with an analogue scale (pain intensity score).

Results

Patients treated with parecoxib 80 mg reported significantly lower summed pain intensity scores compared with lornoxicam and diclofenac-treated patients. Duration of analgesia was also significantly longer with parecoxib than with lornoxicam and diclofenac. Adverse events were significantly less common in the parecoxib and lornoxicam group, compared with diclofenac group.

Conclusions

Multiple-day administration of parecoxib 40 mg twice daily is more effective than equivalent doses of lornoxicam and diclofenac, and generally better tolerated than diclofenac after Lichtenstein tension-free mesh inguinal hernia repair.

Bisgaard T, Klarskov B, Rosenberg J et al (2001) Characteristics and prediction of early pain after laparoscopic cholecystectomy. Pain 90:261–269CrossRefPubMed

Stichtenoth DO, Frolich JC (2003) The second generation of COX-2 inhibitors: what advantages do the newest offer? Drugs 63:33–45CrossRefPubMed

McMurray RW, Hardy KJ (2002) COX-2 inhibitors: today and tomorrow. Am J Med Sci 323:181–189CrossRefPubMed

Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, Verburg KM, Isakson PC, Hubbard RC, Geis GS (1999) Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 354(9196):2106–2111CrossRefPubMed

Deeks J, Smith L, Bradley M (2002) Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 325:619CrossRefPubMed

Rasmusen G, Steckner K, Hogue C et al (2002) Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. Am J Orthop 31:336–343

Barton S, Langeland F, Snabes M et al (2002) Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology 96:306–314CrossRef

Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nat New Biol 231:232–235PubMed

Masferrer JL, Zweifel BS, Seibert K et al (1990) Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 86:1375–1379CrossRefPubMed

10.

Xie W, Chipman JG, Robertson DL et al (1991) Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 88:2692–2696CrossRefPubMed

11.

Beiche F, Scheuerer S, Brune K et al (1996) Upregulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett 390:165–169CrossRefPubMed

12.

Bombardier C, Laine L, Reicin A et al (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343:1520–1528CrossRefPubMed

13.

Schnitzer TJ, Burmester GR, Mysler E et al (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364:665–674CrossRefPubMed

14.

Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A et al (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. J Am Med Assoc 284:1247–1255CrossRef

15.

Chan FK, Hung LC, Suen BY et al (2002) Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347:2104–2110CrossRefPubMed

16.

Lai KC, Chu KM, Hui WM et al (2005) Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 118:1271–1278CrossRefPubMed

17.

Rodrigues AD, Halpin RA, Geer LA, Cui D, Woolf EJ, Matthews CZ, Gottesdiener KM, Larson PJ (2003) Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. Drug Metab Dispos 31:224–232CrossRefPubMed

18.

Esser R, Berry C, Du Z et al (2005) Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol 144:538–550CrossRefPubMed

19.

Szczeklik A, Nizankowska E, Bochenek G et al (2001) Safety of a specific COX₂ inhibitor in aspirin-induced asthma. Clin Exp Allergy 31:219–225CrossRefPubMed

20.

Farkouh ME, Kirshner H, Harrington RA et al (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364:675–684CrossRefPubMed

21.

Capone ML, Tacconelli S, Sciulli MG et al (2004) Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 109:1468–1471CrossRefPubMed

22.

Meagher EA (2004) Cardiovascular and renovascular implications of COX-2 inhibition. Curr Pharm Des 10:603–611CrossRefPubMed

23.

Viscusi E, Gimbel J, Halder A et al (2008) A multiple-day regimen of parecoxib sodium 20 mg twice daily provides pain relief after total hip arthroplasty. Anesth Analg 107:652–660CrossRefPubMed

24.

Joshi GP, Viiscusi ER, Gan TJ et al (2004) Effective treatment of laparoscopic cholecystectomy pain with intravenous followed by oral COX-2 specific inhibitor. Anesth Analg 98:336–342CrossRefPubMed

25.

Papadima A, Lagoudianakis E, Antonakis P et al (2007) Parecoxib vs. Lornoxicam in the treatment of postoperative pain after laparoscopic cholecystectomy: a prospective randomized placebo-controlled trial. Eur J Anaesthesiol 24(2):154–158CrossRefPubMed

26.

Tang J, Li S, White PF, Chen X, Wender RH, Quon R, Sloninsky A, Naruse R, Kariger R, Webb T, Norel E (2002) Effect of parecoxib, a novel intravenous cyclooxygenase type-2 inhibitor, on the postoperative opioid requirement and quality of pain control. Anesthesiology 96(6):1305–1309CrossRefPubMed

27.

Nussmeier NA, Whelton AA, Brown MT et al (2006) Safety and efficacy of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib after noncardiac surgery. Anesthesiology 104(3):518–526CrossRefPubMed

28.

Beaussier M, Weickmans H, Paugam C et al (2005) A randomized, double-blind comparison between parecoxib sodium and propacetamol for parenteral postoperative analgesia after inguinal hernia repair in adult patients. Anesth Analg 100:1309–1315CrossRefPubMed

29.

Kranke P, Morin A, Roewer N et al (2004) Patients’ global evaluation of analgesia and safety of injected parecoxib for postoperative pain: a quantitative systematic review. Anesth Analg 99:797–806CrossRefPubMed

30.

Narchi P, Carry PY, Catoire P (1998) Postoperative pain relief and recovery with ropivacaine infiltration after inguinal hernia repair. Ambul Surg 6(4):221–226CrossRef

31.

Aasbø V, Thuen A, Ræder J (2002) Improved long-lasting postoperative analgesia, recovery function and patient satisfaction after inguinal hernia repair with inguinal field block compared with general anesthesia. Acta Anaesth Scand 46(6):674–678CrossRefPubMed

32.

Harrison CA, Morris S, Harvey JS (1994) Effect of ilioinguinal and iliohypogastric nerve block and wound infiltration with 0.5% bupivacaine on postoperative pain after hernia repair. Brit J Anaesth 72(6):691–693CrossRefPubMed

33.

Vintar N, Pozlep G, Rawal N, Godec M, Rakovec S (2002) Incisional self-administration of bupivacaine or ropivacaine provides effective analgesia after inguinal hernia repair. Can J Anesth 49(5):481–486CrossRefPubMed

Title: Parecoxib sodium in the treatment of postoperative pain after Lichtenstein tension-free mesh inguinal hernia repair
Authors: A. V. Kyriakidis
I. Perysinakis
I. Alexandris
K. Athanasiou
Ch. Papadopoulos
I. Mpesikos
Publication date: 01-02-2011
Publisher: Springer-Verlag
Published in: Hernia / Issue 1/2011
Print ISSN: 1265-4906
Electronic ISSN: 1248-9204
DOI: https://doi.org/10.1007/s10029-010-0737-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Parecoxib sodium in the treatment of postoperative pain after Lichtenstein tension-free mesh inguinal hernia repair

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2011

Bochdalek hernia in the adult: demographics, presentation, and surgical management

Omental incarceration may cause hydrocele and this hydrocele confused simple or scrotal hydrocele

Composite mesh migration into the sigmoid colon following ventral hernia repair

Assessing the risk of clopidogrel-related bleeding complications in patients undergoing inguinal herniorrhaphy

Traumatic diaphragmatic hernia presenting as a tension fecopneumothorax

Anisotropic evaluation of synthetic surgical meshes